Ernexa Therapeutics (NASDAQ:ERNA) Issues Earnings Results, Misses Expectations By $0.10 EPS

Ernexa Therapeutics (NASDAQ:ERNA) released its quarterly earnings results on Thursday. The company reported ($3.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.30) by ($0.10), FiscalAI reports.

Ernexa Therapeutics Stock Performance

Shares of NASDAQ ERNA traded down $0.15 during trading on Friday, reaching $4.21. The stock had a trading volume of 25,279 shares, compared to its average volume of 1,388,595. Ernexa Therapeutics has a one year low of $3.18 and a one year high of $71.50. The stock has a market cap of $4.93 million, a PE ratio of -0.16 and a beta of 2.57. The firm’s 50 day moving average price is $5.88 and its two-hundred day moving average price is $8.85.

Hedge Funds Weigh In On Ernexa Therapeutics

A hedge fund recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new position in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 70.55% of the company’s stock.

Analyst Ratings Changes

ERNA has been the subject of a number of recent analyst reports. Zacks Research upgraded Ernexa Therapeutics to a “hold” rating in a research note on Monday, May 11th. Wall Street Zen lowered shares of Ernexa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Ernexa Therapeutics in a research report on Friday, July 17th. Finally, Brookline Capital Markets assumed coverage on shares of Ernexa Therapeutics in a research note on Thursday, May 7th. They issued a “buy” rating and a $30.00 target price on the stock. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $30.00.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.